Article
SIRT1 silencing promotes EMT and Crizotinib resistance by regulating autophagy through AMPK/mTOR/S6K signaling pathway in EML4-ALK L1196M and EML4-ALK G1202R mutant non-small cell lung cancer cells.
Molecular carcinogenesis - 1 Nov 2024
Yang Qian, Sun Keyan, Gao Tianyu, Gao Ying, Yang Yuying, Li Zengqiang, Zuo Daiying
Abstract excerpt
Most EML4-ALK rearrangement non-small cell lung cancer (NSCLC) patients inevitably develop acquired drug resistance after treatment. The main mechanism of drug resistance is the acquired secondary mutation of ALK kinase domain. L1196M and G1202R are classical mutation sites. We urgently need to understand the underlying molecular mechanism of drug resistance to study the therapeutic targets of mutant...
Topics
Join the communities discussing this publication.